{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:15:59Z","timestamp":1793495759866,"version":"4.5.0"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","award":["BEVP33P01S12168"],"award-info":[{"award-number":["BEVP33P01S12168"]}],"id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800048C"],"award-info":[{"award-number":["HHSN272201800048C"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00051"],"award-info":[{"award-number":["75N93019C00051"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01456-2","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T18:36:08Z","timestamp":1777746968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A TRAC-478-adjuvanted recombinant N1 neuraminidase influenza virus vaccine induces balanced and broadly protective immune responses"],"prefix":"10.1038","volume":"11","author":[{"given":"Irene","family":"Hoxie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Vasilev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardik","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garazi","family":"Pe\u00f1a Alzua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Puente-Massaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Siram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"Tee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Burkhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay T.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"1456_CR1","doi-asserted-by":"publisher","first-page":"12665","DOI":"10.1128\/JVI.78.22.12665-12667.2004","volume":"78","author":"MN Matrosovich","year":"2004","unstructured":"Matrosovich, M. N., Matrosovich, T. Y., Gray, T., Roberts, N. A. & Klenk, H.-D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 78, 12665\u201312667 (2004).","journal-title":"J. Virol."},{"key":"1456_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/1743-422X-10-321","volume":"10","author":"M Cohen","year":"2013","unstructured":"Cohen, M. et al. Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol. J. 10, 321 (2013).","journal-title":"Virol. J."},{"key":"1456_CR3","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.1128\/JVI.02537-14","volume":"89","author":"M Zanin","year":"2015","unstructured":"Zanin, M. et al. Pandemic swine H1N1 influenza viruses with almost undetectable neuraminidase activity are not transmitted via aerosols in ferrets and are inhibited by human mucus but not swine mucus. J. Virol. 89, 5935\u20135948 (2015).","journal-title":"J. Virol."},{"key":"1456_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001136","volume":"6","author":"CM Carlson","year":"2010","unstructured":"Carlson, C. M. et al. Transforming growth factor-\u03b2: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis. PLoS Pathog. 6, e1001136 (2010).","journal-title":"PLoS Pathog."},{"key":"1456_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.chom.2019.10.003","volume":"26","author":"IM Gilchuk","year":"2019","unstructured":"Gilchuk, I. M. et al. Influenza H7N9 virus neuraminidase-specific human monoclonal antibodies inhibit viral egress and protect from lethal influenza infection in mice. Cell Host Microbe 26, 715\u2013728.e8 (2019).","journal-title":"Cell Host Microbe"},{"key":"1456_CR6","doi-asserted-by":"publisher","first-page":"e20241930","DOI":"10.1084\/jem.20241930","volume":"222","author":"A Madsen","year":"2025","unstructured":"Madsen, A. et al. Identification of a seasonal influenza vaccine-induced broadly protective neuraminidase antibody. J. Exp. Med 222, e20241930 (2025).","journal-title":"J. Exp. Med"},{"key":"1456_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.chom.2024.12.004","volume":"33","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Identification of a broad-inhibition influenza neuraminidase antibody from pre-existing memory B cells. Cell Host Microbe 33, 151\u2013166.e8 (2025).","journal-title":"Cell Host Microbe"},{"key":"1456_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cell.2018.03.030","volume":"173","author":"Y-Q Chen","year":"2018","unstructured":"Chen, Y.-Q. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173, 417\u2013429.e10 (2018).","journal-title":"Cell"},{"key":"1456_CR9","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.immuni.2023.10.005","volume":"56","author":"R Lei","year":"2023","unstructured":"Lei, R. et al. Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase. Immunity 56, 2621\u20132634.e6 (2023).","journal-title":"Immunity"},{"key":"1456_CR10","doi-asserted-by":"publisher","first-page":"10910","DOI":"10.1038\/s41467-025-65283-0","volume":"16","author":"G Hoy","year":"2025","unstructured":"Hoy, G. et al. Anti-neuraminidase and anti-HA stalk antibodies reduce the susceptibility to and infectivity of influenza A\/H3N2 virus. Nat Commun 16, 10910 (2025).","journal-title":"Nat Commun"},{"key":"1456_CR11","first-page":"647","volume":"41","author":"JL Schulman","year":"1969","unstructured":"Schulman, J. L. The role of antineuraminidase antibody in immunity to influenza virus infection. Bull. World Health Organ. 41, 647\u2013650 (1969).","journal-title":"Bull. World Health Organ."},{"key":"1456_CR12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJM197206222862502","volume":"286","author":"BR Murphy","year":"1972","unstructured":"Murphy, B. R., Kasel, J. A. & Chanock, R. M. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N. Engl. J. Med. 286, 1329\u20131332 (1972).","journal-title":"N. Engl. J. Med."},{"key":"1456_CR13","doi-asserted-by":"publisher","first-page":"e26335","DOI":"10.1371\/journal.pone.0026335","volume":"6","author":"G Marcelin","year":"2011","unstructured":"Marcelin, G. et al. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. PLoS ONE 6, e26335 (2011).","journal-title":"PLoS ONE"},{"key":"1456_CR14","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/infdis\/jis935","volume":"207","author":"RB Couch","year":"2013","unstructured":"Couch, R. B. et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J. Infect. Dis. 207, 974\u2013981 (2013).","journal-title":"J. Infect. Dis."},{"key":"1456_CR15","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1093\/cid\/ciz639","volume":"70","author":"HE Maier","year":"2020","unstructured":"Maier, H. E. et al. Pre-existing antineuraminidase antibodies are associated with shortened duration of influenza A(H1N1)pdm virus shedding and illness in naturally infected adults. Clin. Infect. Dis. 70, 2290\u20132297 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"1456_CR16","doi-asserted-by":"publisher","first-page":"20748","DOI":"10.1073\/pnas.1113801108","volume":"108","author":"MR Sandbulte","year":"2011","unstructured":"Sandbulte, M. R. et al. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc. Natl. Acad. Sci. USA 108, 20748\u201320753 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1456_CR17","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1073\/pnas.87.2.786","volume":"87","author":"ED Kilbourne","year":"1990","unstructured":"Kilbourne, E. D., Johansson, B. E. & Grajower, B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl. Acad. Sci. USA 87, 786\u2013790 (1990).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1456_CR18","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1093\/cid\/ciz1198","volume":"71","author":"CD Weiss","year":"2020","unstructured":"Weiss, C. D. et al. Neutralizing and neuraminidase antibodies correlate with protection against influenza during a late season A\/H3N2 outbreak among unvaccinated military recruits. Clin. Infect. Dis. 71, 3096\u20133102 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"1456_CR19","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1128\/JVI.02434-12","volume":"87","author":"S Rockman","year":"2013","unstructured":"Rockman, S. et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J. Virol. 87, 3053\u20133061 (2013).","journal-title":"J. Virol."},{"key":"1456_CR20","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.3390\/vaccines10111856","volume":"10","author":"MZ Levine","year":"2022","unstructured":"Levine, M. Z. et al. Influenza A(H7N9) pandemic preparedness: assessment of the breadth of heterologous antibody responses to emerging viruses from multiple pre-pandemic vaccines and population immunity. Vaccines. 10, 1856 (2022).","journal-title":"Vaccines."},{"key":"1456_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126994","volume":"54","author":"F Krammer","year":"2025","unstructured":"Krammer, F. Next-generation seasonal influenza virus vaccines need a neuraminidase component. Vaccine 54, 126994 (2025).","journal-title":"Vaccine"},{"key":"1456_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01057-23","volume":"97","author":"M McMahon","year":"2023","unstructured":"McMahon, M. et al. Immunity induced by vaccination with recombinant influenza B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an exposure intensity-dependent manner. J. Virol. 97, e0105723 (2023).","journal-title":"J. Virol."},{"key":"1456_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02556-14","volume":"6","author":"TJ Wohlbold","year":"2015","unstructured":"Wohlbold, T. J. et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. MBio. 6, e02556 (2015).","journal-title":"MBio"},{"key":"1456_CR24","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0264-410X(97)00279-X","volume":"16","author":"BE Johansson","year":"1998","unstructured":"Johansson, B. E., Matthews, J. T. & Kilbourne, E. D. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine. 16, 1009\u20131015 (1998).","journal-title":"Vaccine"},{"key":"1456_CR25","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0264-410X(01)00490-X","volume":"20","author":"BE Johansson","year":"2002","unstructured":"Johansson, B. E., Pokorny, B. A. & Tiso, V. A. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine. 20, 1670\u20131674 (2002).","journal-title":"Vaccine"},{"key":"1456_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.4161\/hv.4.6.6201","volume":"4","author":"BE Johansson","year":"2008","unstructured":"Johansson, B. E. & Brett, I. C. Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines. Hum. Vaccines 4, 420\u2013424 (2008).","journal-title":"Hum. Vaccines"},{"key":"1456_CR27","doi-asserted-by":"publisher","first-page":"10366","DOI":"10.1128\/JVI.01035-10","volume":"84","author":"BJ Bosch","year":"2010","unstructured":"Bosch, B. J. et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J. Virol. 84, 10366\u201310374 (2010).","journal-title":"J. Virol."},{"key":"1456_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01011-x","volume":"9","author":"G Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s, G. et al. Boosting neuraminidase immunity in the presence of hemagglutinin with the next generation of influenza vaccines. npj Vaccines 9, 228 (2024).","journal-title":"npj Vaccines"},{"key":"1456_CR29","doi-asserted-by":"publisher","first-page":"2304393","DOI":"10.1080\/21645515.2024.2304393","volume":"20","author":"B Li","year":"2024","unstructured":"Li, B. et al. Formulation development of a stable influenza recombinant neuraminidase vaccine candidate. Hum. Vaccine Immunother. 20, 2304393 (2024).","journal-title":"Hum. Vaccine Immunother."},{"key":"1456_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02241-21","volume":"12","author":"S Strohmeier","year":"2021","unstructured":"Strohmeier, S. et al. A novel recombinant influenza virus neuraminidase vaccine candidate stabilized by a measles virus phosphoprotein tetramerization domain provides robust protection from virus challenge in the mouse model. MBio 12, e0224121 (2021).","journal-title":"MBio"},{"key":"1456_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00486-w","volume":"7","author":"S Strohmeier","year":"2022","unstructured":"Strohmeier, S. et al. A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice. npj Vaccines 7, 81 (2022).","journal-title":"npj Vaccines"},{"key":"1456_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126269","volume":"42","author":"I Hoxie","year":"2024","unstructured":"Hoxie, I. et al. A recombinant N2 neuraminidase-based CpG 1018\u00ae adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters. Vaccine 42, 126269 (2024).","journal-title":"Vaccine"},{"key":"1456_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01209-7","volume":"10","author":"K Vasilev","year":"2025","unstructured":"Vasilev, K. et al. Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza vaccine with bacterial cell membrane-derived adjuvants. npj Vaccines 10, 149 (2025).","journal-title":"npj Vaccines"},{"key":"1456_CR34","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1016\/j.vaccine.2016.06.080","volume":"34","author":"AJ Smith","year":"2016","unstructured":"Smith, A. J. et al. Evaluation of novel synthetic TLR7\/8 agonists as vaccine adjuvants. Vaccine 34, 4304\u20134312 (2016).","journal-title":"Vaccine"},{"key":"1456_CR35","doi-asserted-by":"publisher","first-page":"948770","DOI":"10.3389\/fmicb.2022.948770","volume":"13","author":"J Dai","year":"2022","unstructured":"Dai, J. et al. Toll-like receptor signaling in severe acute respiratory syndrome Coronavirus 2-induced innate immune responses and the potential application value of toll-like receptor immunomodulators in patients with Coronavirus disease 2019. Front. Microbiol. 13, 948770 (2022).","journal-title":"Front. Microbiol."},{"key":"1456_CR36","doi-asserted-by":"publisher","unstructured":"Lu, H. et al. Supplementary figure 2 from VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. https:\/\/doi.org\/10.1158\/1078-0432.22445076.v1 (2023).","DOI":"10.1158\/1078-0432.22445076.v1"},{"key":"1456_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80957-z","volume":"11","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent. Sci. Rep. 11, 1535 (2021).","journal-title":"Sci. Rep."},{"key":"1456_CR38","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1200\/jco.2011.29.15_suppl.2537","volume":"29","author":"PA Cohen","year":"2011","unstructured":"Cohen, P. A. et al. Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors. J. Clin. Oncol. 29, 2537\u20132537 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1456_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.976686","volume":"10","author":"H Huang","year":"2022","unstructured":"Huang, H. et al. SARS-CoV-2 delta (B.1.617.2) spike protein adjuvanted with Alum-3M-052 enhances antibody production and neutralization ability. Front. Public Health 10, 976686 (2022).","journal-title":"Front. Public Health"},{"key":"1456_CR40","doi-asserted-by":"publisher","first-page":"738","DOI":"10.4049\/jimmunol.1000060","volume":"185","author":"S Spranger","year":"2010","unstructured":"Spranger, S. et al. Generation of Th1-polarizing dendritic cells using the TLR7\/8 agonist CL075. J. Immunol. 185, 738\u2013747 (2010).","journal-title":"J. Immunol."},{"key":"1456_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00694-y","volume":"8","author":"SM Miller","year":"2023","unstructured":"Miller, S. M. et al. A lipidated TLR7\/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice. npj Vaccines 8, 97 (2023).","journal-title":"npj Vaccines"},{"key":"1456_CR42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s44298-024-00038-0","volume":"2","author":"SK Lathrop","year":"2024","unstructured":"Lathrop, S. K. et al. Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1. npj Viruses 2, 28 (2024).","journal-title":"npj Viruses"},{"key":"1456_CR43","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1126\/science.1113319","volume":"309","author":"SL Werner","year":"2005","unstructured":"Werner, S. L., Barken, D. & Hoffmann, A. Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science. 309, 1857\u20131861 (2005).","journal-title":"Science"},{"key":"1456_CR44","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/90609","volume":"2","author":"S Akira","year":"2001","unstructured":"Akira, S., Takeda, K. & Kaisho, T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2, 675\u2013680 (2001).","journal-title":"Nat. Immunol."},{"key":"1456_CR45","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jconrel.2019.10.025","volume":"315","author":"KK Short","year":"2019","unstructured":"Short, K. K. et al. Co-encapsulation of synthetic lipidated TLR4 and TLR7\/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity. J. Control. Release 315, 186\u2013196 (2019).","journal-title":"J. Control. Release"},{"key":"1456_CR46","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1177\/1753425918771178","volume":"24","author":"N Surendran","year":"2018","unstructured":"Surendran, N., Simmons, A. & Pichichero, M. E. TLR agonist combinations that stimulate Th type I polarizing responses from human neonates. Innate Immun. 24, 240\u2013251 (2018).","journal-title":"Innate Immun."},{"key":"1456_CR47","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.imlet.2017.10.015","volume":"193","author":"M Nouri-Shirazi","year":"2018","unstructured":"Nouri-Shirazi, M., Tamjidi, S., Nourishirazi, E. & Guinet, E. TLR8 combined withTLR3 or TLR4 agonists enhances DC-NK driven effector Tc1 cells. Immunol. Lett. 193, 58\u201366 (2018).","journal-title":"Immunol. Lett."},{"key":"1456_CR48","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1128\/JVI.03337-14","volume":"89","author":"PH Goff","year":"2015","unstructured":"Goff, P. H. et al. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. J. Virol. 89, 3221\u20133235 (2015).","journal-title":"J. Virol."},{"key":"1456_CR49","doi-asserted-by":"publisher","first-page":"e0148984","DOI":"10.1371\/journal.pone.0148984","volume":"11","author":"PF McKay","year":"2016","unstructured":"McKay, P. F. et al. TLR4 and TLR7\/8 adjuvant combinations generate different vaccine antigen-specific immune outcomes in minipigs when administered via the ID or IN routes. PLoS ONE 11, e0148984 (2016).","journal-title":"PLoS ONE"},{"key":"1456_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/pharmaceutics16010107","volume":"16","author":"WM Abdelwahab","year":"2024","unstructured":"Abdelwahab, W. M. et al. Co-delivery of a novel lipidated TLR7\/8 agonist and hemagglutinin-based influenza antigen using silica nanoparticles promotes enhanced immune responses. Pharmaceutics 16, 107 (2024).","journal-title":"Pharmaceutics"},{"key":"1456_CR51","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/ni758","volume":"3","author":"H Hemmi","year":"2002","unstructured":"Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3, 196\u2013200 (2002).","journal-title":"Nat. Immunol."},{"key":"1456_CR52","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1126\/science.1093620","volume":"303","author":"F Heil","year":"2004","unstructured":"Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303, 1526\u20131529 (2004).","journal-title":"Science"},{"key":"1456_CR53","doi-asserted-by":"publisher","first-page":"13900","DOI":"10.1021\/acs.jmedchem.3c00724","volume":"66","author":"JK Khalaf","year":"2023","unstructured":"Khalaf, J. K. et al. Diamino allose phosphates: novel, potent, and highly stable toll-like receptor 4 agonists. J. Med. Chem. 66, 13900\u201313917 (2023).","journal-title":"J. Med. Chem."},{"key":"1456_CR54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/vaccines12010021","volume":"12","author":"K Siram","year":"2023","unstructured":"Siram, K. et al. Co-delivery of novel synthetic TLR4 and TLR7\/8 ligands adsorbed to aluminum salts promotes Th1-mediated immunity against poorly immunogenic SARS-CoV-2 RBD. Vaccines 12, 21 (2023).","journal-title":"Vaccines"},{"key":"1456_CR55","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41541-025-01215-9","volume":"10","author":"M W Crawford","year":"2025","unstructured":"Crawford, M. W. et al. The TLR7\/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine. npj Vaccines 10, 156 (2025).","journal-title":"npj Vaccines"},{"key":"1456_CR56","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1124\/jpet.122.534700","volume":"385","author":"M Raleigh","year":"2023","unstructured":"Raleigh, M. et al. TLR agonist INI-4001 improves efficacy of heroin vaccine intended for clinical treatment of opioid use disorder. J. Pharmacol. Exp. Ther. 385, 119 (2023).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1456_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00697-9","volume":"8","author":"B Crouse","year":"2023","unstructured":"Crouse, B. et al. A TLR7\/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models. npj Vaccines 8, 107 (2023).","journal-title":"npj Vaccines"},{"key":"1456_CR58","doi-asserted-by":"publisher","first-page":"245.12","DOI":"10.4049\/jimmunol.204.Supp.245.12","volume":"204","author":"SL Cole","year":"2020","unstructured":"Cole, S. L. et al. Influenza vaccines using liposomal formulations of toll-like receptor (TLR) 7\/8 and 4 agonists as adjuvants. J. Immunol. 204, 245.12\u2013245.12 (2020).","journal-title":"J. Immunol."},{"key":"1456_CR59","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jconrel.2013.07.030","volume":"172","author":"MT Orr","year":"2013","unstructured":"Orr, M. T. et al. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J. Control. Release 172, 190\u2013200 (2013).","journal-title":"J. Control. Release"},{"key":"1456_CR60","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3389\/fimmu.2017.01077","volume":"8","author":"M Ebrahimian","year":"2017","unstructured":"Ebrahimian, M. et al. Co-delivery of dual toll-like receptor agonists and antigen in poly(lactic-co-glycolic) acid\/polyethylenimine cationic hybrid nanoparticles promote efficient in vivo immune responses. Front. Immunol. 8, 1077 (2017).","journal-title":"Front. Immunol."},{"key":"1456_CR61","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1126\/science.1087262","volume":"301","author":"M Yamamoto","year":"2003","unstructured":"Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301, 640\u2013643 (2003).","journal-title":"Science"},{"key":"1456_CR62","doi-asserted-by":"publisher","first-page":"e01050","DOI":"10.1128\/JVI.01050-17","volume":"91","author":"PH Goff","year":"2017","unstructured":"Goff, P. H. et al. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands work additively via MyD88 to induce protective antiviral immunity in mice. J. Virol 91, e01050\u201317 (2017).","journal-title":"J. Virol"},{"key":"1456_CR63","doi-asserted-by":"publisher","first-page":"e0119509","DOI":"10.1371\/journal.pone.0119509","volume":"10","author":"SL Lambert","year":"2015","unstructured":"Lambert, S. L. et al. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. PLoS ONE 10, e0119509 (2015).","journal-title":"PLoS ONE"},{"key":"1456_CR64","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1080\/21645515.2015.1046660","volume":"11","author":"V Iyer","year":"2015","unstructured":"Iyer, V. et al. Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants. Hum. Vaccin. Immunother. 11, 1853\u20131864 (2015).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1456_CR65","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40005-018-0406-4","volume":"49","author":"R Bastola","year":"2019","unstructured":"Bastola, R. & Lee, S. Physicochemical properties of particulate vaccine adjuvants: their pivotal role in modulating immune responses. J. Pharm. Investig. 49, 279\u2013285 (2019).","journal-title":"J. Pharm. Investig."},{"key":"1456_CR66","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787\u2013796 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"1456_CR67","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.4155\/tde.11.68","volume":"2","author":"C Foged","year":"2011","unstructured":"Foged, C. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Ther. Deliv. 2, 1057\u20131077 (2011).","journal-title":"Ther. Deliv."},{"key":"1456_CR68","doi-asserted-by":"publisher","first-page":"11169","DOI":"10.1073\/pnas.1107941108","volume":"108","author":"A Seubert","year":"2011","unstructured":"Seubert, A. et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc. Natl. Acad. Sci. USA 108, 11169\u201311174 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1456_CR69","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","volume":"29","author":"S Morel","year":"2011","unstructured":"Morel, S. et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29, 2461\u20132473 (2011).","journal-title":"Vaccine"},{"key":"1456_CR70","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.vaccine.2010.12.090","volume":"29","author":"S Calabro","year":"2011","unstructured":"Calabro, S. et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29, 1812\u20131823 (2011).","journal-title":"Vaccine"},{"key":"1456_CR71","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","volume":"30","author":"DT Ohagan","year":"2012","unstructured":"Ohagan, D. T., Ott, G. S., Gregorio, D. & Seubert, E. The mechanism of action of MF59 - An innately attractive adjuvant formulation. Vaccine 30, 4341\u20134348 (2012).","journal-title":"Vaccine"},{"key":"1456_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01130-z","volume":"10","author":"SM Lee","year":"2025","unstructured":"Lee, S. M. et al. Emulsion adjuvant-induced uric acid release modulates optimal immunogenicity by targeting dendritic cells and B cells. npj Vaccines 10, 72 (2025).","journal-title":"npj Vaccines"},{"key":"1456_CR73","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3390\/pharmaceutics14071455","volume":"14","author":"KK Short","year":"2022","unstructured":"Short, K. K. et al. Using dual toll-like receptor agonism to drive Th1-biased response in a squalene- and alpha-tocopherol-containing emulsion for a more effective SARS-CoV-2 vaccine. Pharmaceutics 14, 1455 (2022).","journal-title":"Pharmaceutics"},{"key":"1456_CR74","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","volume":"14","author":"E-J Ko","year":"2018","unstructured":"Ko, E.-J. & Kang, S.-M. Immunology and efficacy of MF59-adjuvanted vaccines. Hum. Vaccine Immunother. 14, 3041\u20133045 (2018).","journal-title":"Hum. Vaccine Immunother."},{"key":"1456_CR75","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1128\/CVI.05441-11","volume":"19","author":"M Baz","year":"2012","unstructured":"Baz, M. et al. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A\/H3N2 influenza vaccines in mice. Clin. Vaccine Immunol. 19, 209\u2013218 (2012).","journal-title":"Clin. Vaccine Immunol."},{"key":"1456_CR76","doi-asserted-by":"publisher","first-page":"eabi4547","DOI":"10.1126\/scitranslmed.abi4547","volume":"13","author":"JR Francica","year":"2021","unstructured":"Francica, J. R. et al. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Sci. Transl. Med 13, eabi4547 (2021).","journal-title":"Sci. Transl. Med"},{"key":"1456_CR77","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1084\/jem.181.2.713","volume":"181","author":"CS Hsieh","year":"1995","unstructured":"Hsieh, C. S., Macatonia, S. E., O\u2019Garra, A. & Murphy, K. M. T cell genetic background determines default T helper phenotype development in vitro. J. Exp. Med. 181, 713\u2013721 (1995).","journal-title":"J. Exp. Med."},{"key":"1456_CR78","doi-asserted-by":"publisher","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","volume":"164","author":"CD Mills","year":"2000","unstructured":"Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J. & Hill, A. M. M-1\/M-2 macrophages and the Th1\/Th2 paradigm. J. Immunol. 164, 6166\u20136173 (2000).","journal-title":"J. Immunol."},{"key":"1456_CR79","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.virol.2014.02.011","volume":"454-455","author":"X Lu","year":"2014","unstructured":"Lu, X. et al. Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus. Virology 454-455, 169\u2013175 (2014).","journal-title":"Virology"},{"key":"1456_CR80","doi-asserted-by":"publisher","first-page":"6941","DOI":"10.1016\/j.vaccine.2023.10.005","volume":"41","author":"P Kitikoon","year":"2023","unstructured":"Kitikoon, P. et al. Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection. Vaccine 41, 6941\u20136951 (2023).","journal-title":"Vaccine"},{"key":"1456_CR81","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/vaccines9040404","volume":"9","author":"S Strohmeier","year":"2021","unstructured":"Strohmeier, S., Carre\u00f1o, J. M., Brito, R. N. & Krammer, F. Introduction of cysteines in the stalk domain of recombinant influenza virus N1 neuraminidase enhances protein stability and immunogenicity in mice. Vaccines 9, 404 (2021).","journal-title":"Vaccines"},{"key":"1456_CR82","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.bbrc.2017.09.011","volume":"493","author":"Y-J Kim","year":"2017","unstructured":"Kim, Y.-J. et al. Roles of antibodies to influenza A virus hemagglutinin, neuraminidase, and M2e in conferring cross protection. Biochem. Biophys. Res. Commun. 493, 393\u2013398 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1456_CR83","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1172\/JCI84428","volume":"126","author":"DJ DiLillo","year":"2016","unstructured":"DiLillo, D. J., Palese, P., Wilson, P. C. & Ravetch, J. V. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Investig. 126, 605\u2013610 (2016).","journal-title":"J. Clin. Investig."},{"key":"1456_CR84","doi-asserted-by":"publisher","first-page":"e01667","DOI":"10.1128\/mBio.01667-19","volume":"10","author":"ER Job","year":"2019","unstructured":"Job, E. R. et al. Fc\u03b3 receptors contribute to the antiviral properties of influenza virus neuraminidase-specific antibodies. MBio 10, e01667\u201319 (2019).","journal-title":"MBio"},{"key":"1456_CR85","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41564-019-0401-1","volume":"4","author":"A Yasuhara","year":"2019","unstructured":"Yasuhara, A. et al. Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus. Nat. Microbiol. 4, 1024\u20131034 (2019).","journal-title":"Nat. Microbiol."},{"key":"1456_CR86","doi-asserted-by":"publisher","unstructured":"Pascha, M. N. et al. Fc-dependent protective efficacy of non-inhibitory antibodies targeting influenza A virus neuraminidase is limited by epitope availability. Preprint at https:\/\/doi.org\/10.1101\/2024.09.03.611041 (2024).","DOI":"10.1101\/2024.09.03.611041"},{"key":"1456_CR87","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.cell.2019.03.048","volume":"177","author":"A Watanabe","year":"2019","unstructured":"Watanabe, A. et al. Antibodies to a conserved influenza head interface Epitope protect by an IgG subtype-dependent mechanism. Cell 177, 1124\u20131135.e16 (2019).","journal-title":"Cell"},{"key":"1456_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2017.1290018","volume":"13","author":"S Jegaskanda","year":"2017","unstructured":"Jegaskanda, S., Vanderven, H. A., Wheatley, A. K. & Kent, S. J. Fc or not Fc; that is the question: antibody Fc-receptor interactions are key to universal influenza vaccine design. Hum. Vaccines Immunother. 13, 1\u20139 (2017).","journal-title":"Hum. Vaccines Immunother."},{"key":"1456_CR89","doi-asserted-by":"publisher","first-page":"e00323","DOI":"10.1128\/JVI.00323-20","volume":"94","author":"M Shibuya","year":"2020","unstructured":"Shibuya, M., Aoshi, T., Kuroda, E. & Yoshioka, Y. Murine cross-reactive nonneutralizing polyclonal IgG1 antibodies induced by influenza vaccine inhibit the cross-protective effect of IgG2 against heterologous virus in mice. J. Virol 94, e00323\u201320 (2020).","journal-title":"J. Virol"},{"key":"1456_CR90","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.3346\/jkms.2016.31.10.1560","volume":"31","author":"JH Kim","year":"2016","unstructured":"Kim, J. H. et al. Immunoglobulin G subclass deficiencies in adult patients with chronic airway diseases. J. Korean Med. Sci. 31, 1560\u20131565 (2016).","journal-title":"J. Korean Med. Sci."},{"key":"1456_CR91","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cellimm.2015.09.004","volume":"299","author":"JC Barton","year":"2016","unstructured":"Barton, J. C., Bertoli, L. F., Barton, J. C. & Acton, R. T. Selective subnormal IgG3 in 121 adult index patients with frequent or severe bacterial respiratory tract infections. Cell. Immunol. 299, 50\u201357 (2016).","journal-title":"Cell. Immunol."},{"key":"1456_CR92","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abj1640","volume":"7","author":"S Foss","year":"2022","unstructured":"Foss, S. et al. Potent TRIM21 and complement-dependent intracellular antiviral immunity requires the IgG3 hinge. Sci. Immunol. 7, eabj1640 (2022).","journal-title":"Sci. Immunol."},{"key":"1456_CR93","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107249118","volume":"118","author":"S Kallolimath","year":"2021","unstructured":"Kallolimath, S. et al. Highly active engineered IgG3 antibodies against SARS-CoV-2. Proc. Natl. Acad. Sci. USA 118, e2107249118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1456_CR94","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.1128\/JVI.75.14.6558-6565.2001","volume":"75","author":"O Scharf","year":"2001","unstructured":"Scharf, O. et al. Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1. J. Virol. 75, 6558\u20136565 (2001).","journal-title":"J. Virol."},{"key":"1456_CR95","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.1182\/blood-2010-12-328138","volume":"117","author":"C Russo","year":"2011","unstructured":"Russo, C. et al. Small molecule toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells. Blood 117, 5683\u20135691 (2011).","journal-title":"Blood"},{"key":"1456_CR96","doi-asserted-by":"publisher","first-page":"15665","DOI":"10.1021\/acsomega.9b02138","volume":"4","author":"JT Evans","year":"2019","unstructured":"Evans, J. T. et al. Synthetic toll-like receptors 7 and 8 agonists: structure-activity relationship in the oxoadenine series. ACS Omega 4, 15665\u201315677 (2019).","journal-title":"ACS Omega"},{"key":"1456_CR97","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ejps.2018.07.048","volume":"123","author":"AJR Gadd","year":"2018","unstructured":"Gadd, A. J. R. et al. High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal formulation. Eur. J. Pharm. Sci. 123, 268\u2013276 (2018).","journal-title":"Eur. J. Pharm. Sci."},{"key":"1456_CR98","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg3747","volume":"10","author":"D Soni","year":"2024","unstructured":"Soni, D. et al. From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7\/8 agonist adjuvant formulation. Sci. Adv. 10, eadg3747 (2024).","journal-title":"Sci. Adv."},{"key":"1456_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/srep46426","volume":"7","author":"N Van Hoeven","year":"2017","unstructured":"Van Hoeven, N. et al. A formulated TLR7\/8 agonist is a flexible, highly potent and effective adjuvant for pandemic influenza vaccines. Sci. Rep. 7, 46426 (2017).","journal-title":"Sci. Rep."},{"key":"1456_CR100","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.exppara.2012.09.001","volume":"132","author":"A Badiee","year":"2012","unstructured":"Badiee, A. et al. The role of liposome size on the type of immune response induced in BALB\/c mice against leishmaniasis: Rgp63 as a model antigen. Exp. Parasitol. 132, 403\u2013409 (2012).","journal-title":"Exp. Parasitol."},{"key":"1456_CR101","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1016\/j.vaccine.2009.03.040","volume":"27","author":"JFS Mann","year":"2009","unstructured":"Mann, J. F. S. et al. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1\/Th2 bias in the immune response and protection against infection. Vaccine 27, 3643\u20133649 (2009).","journal-title":"Vaccine"},{"key":"1456_CR102","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1016\/j.biomaterials.2010.01.065","volume":"31","author":"C He","year":"2010","unstructured":"He, C., Hu, Y., Yin, L., Tang, C. & Yin, C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31, 3657\u20133666 (2010).","journal-title":"Biomaterials"},{"key":"1456_CR103","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3389\/fimmu.2020.00406","volume":"11","author":"SM Miller","year":"2020","unstructured":"Miller, S. M. et al. Novel lipidated imidazoquinoline TLR7\/8 adjuvants elicit influenza-specific Th1 immune responses and protect against heterologous H3N2 influenza challenge in mice. Front. Immunol. 11, 406 (2020).","journal-title":"Front. Immunol."},{"key":"1456_CR104","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/sj.cdd.4401850","volume":"13","author":"T Kawai","year":"2006","unstructured":"Kawai, T. & Akira, S. TLR signaling. Cell Death Differ 13, 816\u2013825 (2006).","journal-title":"Cell Death Differ"},{"key":"1456_CR105","doi-asserted-by":"publisher","first-page":"812774","DOI":"10.3389\/fimmu.2022.812774","volume":"13","author":"T Duan","year":"2022","unstructured":"Duan, T., Du, Y., Xing, C., Wang, H. Y. & Wang, R.-F. Toll-like receptor signaling and its role in cell-mediated immunity. Front. Immunol. 13, 812774 (2022).","journal-title":"Front. Immunol."},{"key":"1456_CR106","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fimmu.2014.00316","volume":"5","author":"C Vaure","year":"2014","unstructured":"Vaure, C. & Liu, Y. A comparative review of toll-like receptor 4 expression and functionality in different animal species. Front. Immunol. 5, 316 (2014).","journal-title":"Front. Immunol."},{"key":"1456_CR107","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s13238-012-2104-8","volume":"4","author":"M Bao","year":"2013","unstructured":"Bao, M. & Liu, Y.-J. Regulation of TLR7\/9 signaling in plasmacytoid dendritic cells. Protein Cell 4, 40\u201352 (2013).","journal-title":"Protein Cell"},{"key":"1456_CR108","doi-asserted-by":"publisher","first-page":"729233","DOI":"10.3389\/fimmu.2021.729233","volume":"12","author":"J-C Gu\u00e9ry","year":"2021","unstructured":"Gu\u00e9ry, J.-C. Sex differences in primary HIV infection: Revisiting the role of TLR7-driven type 1 IFN production by plasmacytoid dendritic cells in women. Front. Immunol. 12, 729233 (2021).","journal-title":"Front. Immunol."},{"key":"1456_CR109","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature09737","volume":"470","author":"SP Kasturi","year":"2011","unstructured":"Kasturi, S. P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543\u2013547 (2011).","journal-title":"Nature"},{"key":"1456_CR110","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/nm.3350","volume":"19","author":"S Sridhar","year":"2013","unstructured":"Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19, 1305\u20131312 (2013).","journal-title":"Nat. Med."},{"key":"1456_CR111","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nm.2612","volume":"18","author":"TM Wilkinson","year":"2012","unstructured":"Wilkinson, T. M. et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18, 274\u2013280 (2012).","journal-title":"Nat. Med."},{"key":"1456_CR112","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.chom.2021.10.009","volume":"29","author":"DR McIlwain","year":"2021","unstructured":"McIlwain, D. R. et al. Human influenza virus challenge identifies cellular correlates of protection for oral vaccination. Cell Host Microbe 29, 1828\u20131837.e5 (2021).","journal-title":"Cell Host Microbe"},{"key":"1456_CR113","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3389\/fimmu.2020.01207","volume":"11","author":"F Sato-Kaneko","year":"2020","unstructured":"Sato-Kaneko, F. et al. A novel synthetic dual agonistic liposomal TLR4\/7 adjuvant promotes broad immune responses in an influenza vaccine with minimal reactogenicity. Front. Immunol. 11, 1207 (2020).","journal-title":"Front. Immunol."},{"key":"1456_CR114","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3389\/fimmu.2020.01166","volume":"11","author":"A Choi","year":"2020","unstructured":"Choi, A. et al. Non-sterilizing, infection-permissive vaccination with inactivated influenza virus vaccine reshapes subsequent virus infection-induced protective heterosubtypic immunity from cellular to humoral cross-reactive immune responses. Front. Immunol. 11, 1166 (2020).","journal-title":"Front. Immunol."},{"key":"1456_CR115","doi-asserted-by":"publisher","first-page":"10539","DOI":"10.1128\/JVI.00967-13","volume":"87","author":"D Blumenkrantz","year":"2013","unstructured":"Blumenkrantz, D., Roberts, K. L., Shelton, H., Lycett, S. & Barclay, W. S. The short stalk length of highly pathogenic avian influenza H5N1 virus neuraminidase limits transmission of pandemic H1N1 virus in ferrets. J. Virol. 87, 10539\u201310551 (2013).","journal-title":"J. Virol."},{"key":"1456_CR116","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01478-24","volume":"99","author":"D Kobayashi","year":"2025","unstructured":"Kobayashi, D. et al. Deglycosylation and truncation in the neuraminidase stalk are functionally equivalent in enhancing the pathogenicity of a high pathogenicity avian influenza virus in chickens. J. Virol. 99, e0147824 (2025).","journal-title":"J. Virol."},{"key":"1456_CR117","doi-asserted-by":"publisher","first-page":"e6277","DOI":"10.1371\/journal.pone.0006277","volume":"4","author":"H Zhou","year":"2009","unstructured":"Zhou, H. et al. The special neuraminidase stalk-motif responsible for increased virulence and pathogenesis of H5N1 influenza A virus. PLoS ONE 4, e6277 (2009).","journal-title":"PLoS ONE"},{"key":"1456_CR118","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03989-24","volume":"16","author":"E Hermann","year":"2025","unstructured":"Hermann, E. & Krammer, F. Clade 2.3.4.4b H5N1 neuraminidase has a long stalk, which is in contrast to most highly pathogenic H5N1 viruses circulating between 2002 and 2020. MBio 16, e0398924 (2025).","journal-title":"MBio"},{"key":"1456_CR119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011135","volume":"19","author":"D Scheibner","year":"2023","unstructured":"Scheibner, D. et al. Phenotypic effects of mutations observed in the neuraminidase of human origin H5N1 influenza A viruses. PLoS Pathog. 19, e1011135 (2023).","journal-title":"PLoS Pathog."},{"key":"1456_CR120","doi-asserted-by":"publisher","first-page":"e0220924","DOI":"10.1128\/jvi.02209-24","volume":"99","author":"F Krammer","year":"2025","unstructured":"Krammer, F., Hermann, E. & Rasmussen, A. L. Highly pathogenic avian influenza H5N1: history, current situation, and outlook. J. Virol. 99, e0220924 (2025).","journal-title":"J. Virol."},{"key":"1456_CR121","doi-asserted-by":"publisher","first-page":"34016","DOI":"10.1074\/jbc.M110.115998","volume":"285","author":"AC Bateman","year":"2010","unstructured":"Bateman, A. C. et al. Glycan analysis and influenza A virus infection of primary swine respiratory epithelial cells: the importance of NeuAcalpha2-6 glycans. J. Biol. Chem. 285, 34016\u201334018 (2010).","journal-title":"J. Biol. Chem."},{"key":"1456_CR122","doi-asserted-by":"publisher","first-page":"9221","DOI":"10.1128\/JVI.00697-12","volume":"86","author":"R Xu","year":"2012","unstructured":"Xu, R. et al. Functional balance of the hemagglutinin and neuraminidase activities accompanies the emergence of the 2009 H1N1 influenza pandemic. J. Virol. 86, 9221\u20139232 (2012).","journal-title":"J. Virol."},{"key":"1456_CR123","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/nature08182","volume":"459","author":"GJD Smith","year":"2009","unstructured":"Smith, G. J. D. et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459, 1122\u20131125 (2009).","journal-title":"Nature"},{"key":"1456_CR124","doi-asserted-by":"publisher","first-page":"7367","DOI":"10.1128\/JVI.72.9.7367-7373.1998","volume":"72","author":"T Ito","year":"1998","unstructured":"Ito, T. et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J. Virol. 72, 7367\u20137373 (1998).","journal-title":"J. Virol."},{"key":"1456_CR125","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1056\/NEJMoa0903812","volume":"360","author":"V Shinde","year":"2009","unstructured":"Shinde, V. et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N. Engl. J. Med. 360, 2616\u20132625 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1456_CR126","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/infdis\/jir169","volume":"203","author":"V Sambhara","year":"2011","unstructured":"Sambhara, V. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. J. Infect. Dis. 203, 1697\u20131698 (2011).","journal-title":"J. Infect. Dis."},{"key":"1456_CR127","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1016\/j.vaccine.2009.03.021","volume":"27","author":"K Van Reeth","year":"2009","unstructured":"Van Reeth, K. et al. Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus. Vaccines 27, 6330\u20136339 (2009).","journal-title":"Vaccines"},{"key":"1456_CR128","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.virol.2012.06.003","volume":"432","author":"JD Easterbrook","year":"2012","unstructured":"Easterbrook, J. D. et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 432, 39\u201344 (2012).","journal-title":"Virology"},{"key":"1456_CR129","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040059","volume":"4","author":"MR Sandbulte","year":"2007","unstructured":"Sandbulte, M. R. et al. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4, e59 (2007).","journal-title":"PLoS Med."},{"key":"1456_CR130","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1016\/j.vaccine.2012.01.090","volume":"30","author":"Z Chen","year":"2012","unstructured":"Chen, Z., Kim, L., Subbarao, K. & Jin, H. The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets. Vaccine 30, 2516\u20132522 (2012).","journal-title":"Vaccine"},{"key":"1456_CR131","doi-asserted-by":"publisher","first-page":"7224","DOI":"10.1128\/JVI.00585-15","volume":"89","author":"W-C Liu","year":"2015","unstructured":"Liu, W.-C., Lin, C.-Y., Tsou, Y.-T., Jan, J.-T. & Wu, S.-C. Cross-reactive neuraminidase-inhibiting antibodies elicited by immunization with recombinant neuraminidase proteins of H5N1 and pandemic H1N1 influenza A viruses. J. Virol. 89, 7224\u20137234 (2015).","journal-title":"J. Virol."},{"key":"1456_CR132","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1126\/science.aay0678","volume":"366","author":"D Stadlbauer","year":"2019","unstructured":"Stadlbauer, D. et al. Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science 366, 499\u2013504 (2019).","journal-title":"Science"},{"key":"1456_CR133","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4161\/hv.7.0.14595","volume":"7","author":"Y Shoji","year":"2011","unstructured":"Shoji, Y. et al. An influenza N1 neuraminidase-specific monoclonal antibody with broad neuraminidase inhibition activity against H5N1 HPAI viruses. Hum. Vaccin. 7, 199\u2013204 (2011).","journal-title":"Hum. Vaccin."},{"key":"1456_CR134","doi-asserted-by":"publisher","first-page":"9290","DOI":"10.1128\/JVI.01203-13","volume":"87","author":"H Wan","year":"2013","unstructured":"Wan, H. et al. Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. J. Virol. 87, 9290\u20139300 (2013).","journal-title":"J. Virol."},{"key":"1456_CR135","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.immuni.2023.07.004","volume":"56","author":"L Hansen","year":"2023","unstructured":"Hansen, L. et al. Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo. Immunity. 56, 1927\u20131938.e8 (2023).","journal-title":"Immunity"},{"key":"1456_CR136","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00332-22","volume":"96","author":"E Kirkpatrick Roubidoux","year":"2022","unstructured":"Kirkpatrick Roubidoux, E. et al. Novel epitopes of the influenza virus N1 neuraminidase targeted by human monoclonal antibodies. J. Virol. 96, e0033222 (2022).","journal-title":"J. Virol."},{"key":"1456_CR137","doi-asserted-by":"publisher","first-page":"e02281","DOI":"10.1128\/mBio.02281-16","volume":"8","author":"M Rajendran","year":"2017","unstructured":"Rajendran, M. et al. Analysis of anti-influenza virus neuraminidase antibodies in children, adults, and the elderly by ELISA and enzyme inhibition: Evidence for original antigenic sin. MBio 8, e02281\u201316 (2017).","journal-title":"MBio"},{"key":"1456_CR138","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/ni.3684","volume":"18","author":"R Nachbagauer","year":"2017","unstructured":"Nachbagauer, R. et al. Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nat. Immunol. 18, 464\u2013473 (2017).","journal-title":"Nat. Immunol."},{"key":"1456_CR139","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1126\/science.1097211","volume":"305","author":"DJ Smith","year":"2004","unstructured":"Smith, D. J. et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305, 371\u2013376 (2004).","journal-title":"Science"},{"key":"1456_CR140","doi-asserted-by":"publisher","first-page":"e38665","DOI":"10.1371\/journal.pone.0038665","volume":"7","author":"J Xu","year":"2012","unstructured":"Xu, J. et al. Evolutionary history and phylodynamics of influenza A and B neuraminidase (NA) genes inferred from large-scale sequence analyses. PLoS ONE 7, e38665 (2012).","journal-title":"PLoS ONE"},{"key":"1456_CR141","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/v10040183","volume":"10","author":"P Kim","year":"2018","unstructured":"Kim, P. et al. Glycosylation of hemagglutinin and neuraminidase of influenza A virus as signature for ecological spillover and adaptation among influenza reservoirs. Viruses 10, 183 (2018).","journal-title":"Viruses"},{"key":"1456_CR142","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01695-24","volume":"99","author":"H Lv","year":"2025","unstructured":"Lv, H. et al. Differential antigenic imprinting effects between influenza H1N1 hemagglutinin and neuraminidase in a mouse model. J. Virol. 99, e0169524 (2025).","journal-title":"J. Virol."},{"key":"1456_CR143","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.4049\/jimmunol.139.6.2010","volume":"139","author":"BE Johansson","year":"1987","unstructured":"Johansson, B. E., Moran, T. M., Bona, C. A., Popple, S. W. & Kilbourne, E. D. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J. Immunol. 139, 2010\u20132014 (1987).","journal-title":"J. Immunol."},{"key":"1456_CR144","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-1-0716-3666-4_4","volume":"2762","author":"M Loganathan","year":"2024","unstructured":"Loganathan, M., Francis, B. & Krammer, F. Production of influenza virus glycoproteins using insect cells. Methods Mol. Biol. 2762, 43\u201370 (2024).","journal-title":"Methods Mol. Biol."},{"key":"1456_CR145","first-page":"e51112","volume":"6","author":"I Margine","year":"2013","unstructured":"Margine, I., Palese, P. & Krammer, F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J. Vis. Exp 6, e51112 (2013).","journal-title":"J. Vis. Exp"},{"key":"1456_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113901","volume":"384","author":"FA Hamid","year":"2025","unstructured":"Hamid, F. A. et al. A novel cationic liposome-formulated toll like receptor (TLR) 7\/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity. J. Control. Release 384, 113901 (2025).","journal-title":"J. Control. Release"},{"key":"1456_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35586-7","volume":"13","author":"D Stadlbauer","year":"2022","unstructured":"Stadlbauer, D. et al. Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site. Nat. Commun. 13, 7864 (2022).","journal-title":"Nat. Commun."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01456-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01456-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01456-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:03:58Z","timestamp":1783472638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01456-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":147,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1456"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01456-2","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines influenza virus vaccines (specific filing applying here: WO2021081120A1 WIPO (PCT)\/ US20220403358A1, application filed by Icahn School of Medicine at Mount Sinai, inventors Peter Palese, Adolfo Garcia-Sastre, Florian Krammer) and influenza virus therapeutics which list F.K. as co-inventor and F.K. has received royalty payments from some of these patents. Financial and Non-Financial Interest: Mount Sinai has spun out a company, Castlevax, to develop SARS-CoV-2 vaccines. F.K. is co-founder and scientific advisory board member of Castlevax. F.K. has consulted for Merck, GSK, Sanofi, Gritstone, Curevac, Seqirus and Pfizer and is currently consulting for 3rd Rock Ventures and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza vaccine development. D.B. and J.E. are employees and shareholders of Inimmune Corp., which holds an exclusive license for INI-4001 and issued patents for INI-2002. The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}